Bazedoxifene/conjugated estrogens

Bazedoxifene/conjugated estrogens, sold under the brand name Duavee in the US and Duavive in the EU, is a fixed-dose combination medication for the treatment of menopause symptoms and postmenopausal osteoporosis.[2] It contains the selective estrogen receptor modulator bazedoxifene and conjugated estrogens. It is taken by mouth.

Bazedoxifene/conjugated estrogens
Combination of
BazedoxifeneSelective estrogen receptor modulator
Conjugated estrogensEstrogen
Clinical data
Trade namesDuavee, Duavive
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa614004
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
ChemSpider
  • None
KEGG

The combination was approved for medical use in the United States in October 2013,[3] and in the European Union in December 2014.[4]

Recall

In June 2020, Pfizer recalled recalled two batches of Duavive, its oestrogen replacement product, as a result of concerns raised about faulty packaging.[5]

See also

References
  1. "Bazedoxifene / conjugated estrogens (Duavee) Use During Pregnancy". Drugs.com. 16 February 2019. Retrieved 23 June 2020.
  2. "Duavee. Generic Name: conjugated estrogens and bazedoxifene tablets". rxlist.com.
  3. "Drug Approval Package: Duavee (conjugated estrogens and bazedoxifene) NDA #022247". U.S. Food and Drug Administration (FDA). 7 October 2013. Retrieved 23 June 2020.
  4. "Duavive EPAR". European Medicines Agency (EMA). Retrieved 2020-06-10.
  5. "Pfizer recalls 2 batches of Duavive". Zenopa.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.